1. Haggar FA, Boushey RP. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg. 2009;22:191-7.
2. Marley AR, Nan H. Epidemiology of colorectal cancer. Int J Mol Epidemiol Genet. 2016;7:105-14.
3. Van Cutsem E, Nordlinger B, Cervantes A. Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. Ann Oncol. 2010;21:93-7.
4. Watanabe T, Muro K, Ajioka Y, Hashiguchi Y, Ito Y, Saito Y et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. Int J Clin Oncol. 2018;23:1-34.
5. Benson 3rd AB, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS et al. Metastatic colon cancer, version 3.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2013;11:141-52.
6. Grothey A, Cutsem EV, Sobrero A, Siena S, Falcone A, Ychou M et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381:303-12.
7. Xu R, Yau CC, Li J, Qin S, Xu R, Yau TCC et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2015;16:619-29.
8. Yoshino T, Komatsu Y, Yamada Y, Yamazaki K, Tsuji A, Ura T et al. Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations. Invest New Drugs. 2015;33:740-50..
9. Ben-Ami E, Barysauskas CM, von Mehren M, Heinrich MC, Corless CL, Butrynski JE et al. Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy. Ann Oncol. 2016;27:1794-9.
10. Bekaii-Saab TS, Ou F-S, Anderson DM, Ahn DH, Boland PM, Ciombor KK et al. Regorafenib dose optimization study (ReDOS): Randomized phase II trial to evaluate dosing strategies for regorafenib in refractory metastatic colorectal cancer (mCRC)-An ACCRU Network study. J Clin Oncol. 2018;36: https://doi.org/10.1093/annonc/mdy1149.1013.
11. Hirano G, Makiyama A, Makiyama C, Esaki T, Oda H, Uchino K et al. Reduced dose of salvage-line regorafenib monotherapy for metastatic colorectal cancer in Japan. Anticancer Res. 2015;35:371-7.
12. Yamaguchi K, Komatsu Y, Satoh T, Uetake H, Yoshino T, Nishida T et al. Large-Scale, Prospective Observavtional Study of Regorafenib in Japanese Patients with Metastatic Colorectal Cancer in a Real- World Clinical Setting. Oncologist. 2019; https://doi.org/10.1634/theoncologist.2018-0377.
13. Osawa H. Response to regorafenib at an initial dose of 120 mg as salvage therapy for metastatic colorectal cancer. Mol Clin Oncol. 2017;5;365-72.
14. Kudo T, Kato T, Kagawa Y, Sakai D, Satoh T, Doki Y et al. Phase II dose titration study of regorafenib for patients with unresectable metastatic colorectal cancer that progressed after standard chemmotherapy. J Clin Oncol. 2018; https://ascopubs.org/doi/10.1200/JCO.2018.36.4_suppl.821.
15. Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Epidemiology. 2007;18:805-35.
16. Urushihara H, Taketsuna M, Liu Y, Oda E, Nakamura M, Nishiuma S et al. Increased risk of acute pancreatitis in patients with type 2 diabetes: an observational study using a Japanese hospital database. PloS one. 2012;7(12):e53224.
17. Tanaka S, Seto K, Kawakami K. Pharmacoepidemiology in Japan: medical databases and research achievements. J Pharm Health Care Sci. 2015;1:16.
18. Mross K, Frost A, Steinbild S, Hedbom S, Buchert M, Fasol U et al. A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res. 2012;18:2658-67.
19. Sunakawa Y, Furuse J, Okusaka T, Ikeda M, Nagashima F, Ueno H et al. Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics. Invest New Drugs. 2014;32:104-12.
20. Rubin DB, Thomas N. Matching using estimated propensity scores: relating theory to practice. Biometrics. 1996;52:249-64.
21. Moriwaki T, Fukuoka S, Taniguchi H, Takashima A, Kumekawa Y, Kajiwara T et al. Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study. Oncologist. 2018;23:7-15.
22. Grothey A, George S, van Cutsem E, Blay J-Y, Sobrero A, Demetri GD. Optimizing treatment outcomes with regorafenib: personalized dosing and other strategies to support patient care. Oncologist. 2014;19:669-80.
23. Komatsu Y, Muro K, Yamaguchi K, Satoh T, Uetake H, Yoshino T et al. Safety and efficacy of regorafenib post-marketing surveillance (PMS) in Japanese patients with metastatic colorectal cancer (mCRC). J Clin Oncol. 2017;35:721.
24. Adenis A, de la Fouchardiere C, Paule B, Burtin P, Tougeron D, Wallet J et al. Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program. BMC Cancer. 2016;16:412.
25. Masuishi T, Taniguchi H, Hamauchi S, Komori A, Kito Y, Narita Y et al. Regorafenib Versus Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: A Retrospective Comparison. Clin Colorectal Cancer. 2016;16:12-22. https://doi.10.1016/j.clcc.2016.07.019.
26. Van Cutsem E, Martinelli E, Cascinu S, Sobrero A, Banzi M, Seitz JF et al. Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single- Arm, Open-Label Phase IIIb CONSIGN Study. Oncologist. 2018: https://doi. 10.1634/theoncologist.2018-0072.
27. Strumberg D, Scheulen ME, Schultheis B, Richly H, Frost A, Büchert M et al. Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study. Br J Cancer. 2012;106:1722-7.